• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝门部胆管癌患者的肝移植资格。

Eligibility for Liver Transplantation in Patients with Perihilar Cholangiocarcinoma.

机构信息

Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

出版信息

Ann Surg Oncol. 2021 Mar;28(3):1483-1492. doi: 10.1245/s10434-020-09001-8. Epub 2020 Sep 8.

DOI:10.1245/s10434-020-09001-8
PMID:32901308
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7892510/
Abstract

BACKGROUND

Liver transplantation (LT) has been performed in a select group of patients presenting with unresectable or primary sclerosing cholangitis (PSC)-associated perihilar cholangiocarcinoma (pCCA) in the Mayo Clinic with a reported 5-year overall survival (OS) of 53% on intention-to-treat analysis. The objective of this study was to estimate eligibility for LT in a cohort of pCCA patients in two tertiary referral centers.

METHODS

Patients diagnosed with pCCA between 2002 and 2014 were included from two tertiary referral centers in the Netherlands. The selection criteria used by the Mayo Clinic were retrospectively applied to determine the proportion of patients that would have been eligible for LT.

RESULTS

A total of 732 consecutive patients with pCCA were identified, of whom 24 (4%) had PSC-associated pCCA. Overall, 154 patients had resectable disease on imaging and 335 patients were ineligible for LT because of lymph node or distant metastases. An age limit of 70 years led to the exclusion of 50 patients who would otherwise be eligible for LT. After applying the Mayo Clinic criteria, only 34 patients (5%) were potentially eligible for LT. Median survival from diagnosis for these 34 patients was 13 months (95% CI 3-23).

CONCLUSION

Only 5% of all patients presenting with pCCA were potentially eligible for LT under the Mayo criteria. Without transplantation, a median OS of about 1 year was observed.

摘要

背景

在梅奥诊所,对于无法切除或原发性硬化性胆管炎(PSC)相关的肝门部胆管癌(pCCA)患者,选择性地进行肝移植(LT)治疗,其意向治疗分析的 5 年总生存率(OS)为 53%。本研究的目的是在荷兰的两家三级转诊中心的 pCCA 患者队列中,评估 LT 的入选资格。

方法

从荷兰的两家三级转诊中心中纳入了 2002 年至 2014 年间被诊断为 pCCA 的患者。回顾性应用梅奥诊所的选择标准,以确定有多少患者符合 LT 的入选标准。

结果

共确定了 732 例连续的 pCCA 患者,其中 24 例(4%)患有 PSC 相关的 pCCA。总体而言,154 例患者的影像学表现为可切除病变,335 例患者因淋巴结或远处转移而不符合 LT 标准。年龄限制在 70 岁,导致 50 例本可符合 LT 标准的患者被排除在外。在应用梅奥诊所标准后,仅有 34 例患者(5%)可能符合 LT 标准。这 34 例患者的中位诊断后生存期为 13 个月(95%CI:3-23)。

结论

根据梅奥标准,所有 pCCA 患者中仅有 5%可能符合 LT 的入选标准。若不进行移植,中位 OS 约为 1 年。

相似文献

1
Eligibility for Liver Transplantation in Patients with Perihilar Cholangiocarcinoma.肝门部胆管癌患者的肝移植资格。
Ann Surg Oncol. 2021 Mar;28(3):1483-1492. doi: 10.1245/s10434-020-09001-8. Epub 2020 Sep 8.
2
Can the Limits of Liver Transplantation Be Expanded in Perihilar Cholangiocarcinoma?肝门部胆管癌的肝移植极限能否扩大?
J Gastrointest Cancer. 2022 Dec;53(4):1104-1112. doi: 10.1007/s12029-021-00735-6. Epub 2021 Nov 5.
3
Impact of EUS in liver transplantation workup for patients with unresectable perihilar cholangiocarcinoma.EUS 在不可切除的肝门部胆管癌肝移植术前评估中的作用。
Gastrointest Endosc. 2024 Apr;99(4):548-556. doi: 10.1016/j.gie.2023.10.047. Epub 2023 Oct 27.
4
Outcome after resection for perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis: an international multicentre study.原发性硬化性胆管炎患者肝门周围胆管癌切除术后的结果:一项国际多中心研究。
HPB (Oxford). 2021 Nov;23(11):1751-1758. doi: 10.1016/j.hpb.2021.04.011. Epub 2021 Apr 28.
5
Liver Transplantation for Peri-hilar Cholangiocarcinoma.肝移植治疗肝门部胆管癌。
J Gastrointest Surg. 2020 Nov;24(11):2679-2685. doi: 10.1007/s11605-020-04721-4. Epub 2020 Jul 15.
6
Current Perspectives in Liver Transplantation for Perihilar Cholangiocarcinoma.肝门部胆管癌肝移植的现状。
Curr Oncol. 2023 Mar 1;30(3):2942-2953. doi: 10.3390/curroncol30030225.
7
Single-center experience of liver transplantation for perihilar cholangiocarcinoma.单中心肝移植治疗肝门部胆管癌的经验。
HPB (Oxford). 2022 Apr;24(4):461-469. doi: 10.1016/j.hpb.2021.08.940. Epub 2021 Aug 18.
8
Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma.可切除性肝门部胆管癌患者预后列线图的建立与验证
Oncotarget. 2016 Jun 14;7(24):37319-37330. doi: 10.18632/oncotarget.9104.
9
A New Strategy of Liver Transplantation for Locally Advanced Unresectable Perihilar Cholangiocarcinoma Using Living Grafts With Simultaneous Resection of Recipients' Hepatic Artery and Portal Vein Without Neoadjuvant Radiation: A Case Report.利用活体供肝行肝动脉和门静脉同期切除的新策略治疗局部进展期不可切除的肝门部胆管癌:附 1 例报告
Transplant Proc. 2022 Jul-Aug;54(6):1643-1647. doi: 10.1016/j.transproceed.2022.03.054. Epub 2022 Jul 7.
10
The clinicopathological factors associated with prognosis of patients with resectable perihilar cholangiocarcinoma: A systematic review and meta-analysis.可切除性肝门部胆管癌患者预后相关的临床病理因素:一项系统评价和荟萃分析
Medicine (Baltimore). 2018 Aug;97(34):e11999. doi: 10.1097/MD.0000000000011999.

引用本文的文献

1
Liver hypertrophy techniques: a position paper from the Italian Group of Regenerative and Occlusive Worldwide-used techniques of hepatic Hypertrophy (I GROWtoH).肝脏肥大技术:来自意大利全球肝脏肥大再生与闭塞常用技术小组(I GROWtoH)的立场文件。
Updates Surg. 2025 Aug 26. doi: 10.1007/s13304-025-02364-1.
2
Treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis: a comprehensive review.原发性硬化性胆管炎患者胆管癌的治疗:综述
eGastroenterology. 2024 Mar 29;2(1):e100045. doi: 10.1136/egastro-2023-100045. eCollection 2024 Jan.
3
Assessment of Liver Transplant Eligibility in Chronic Liver Disease Patients: A Cross-Sectional Study From a Tertiary Care Hospital of Pakistan.

本文引用的文献

1
Age and liver transplantation.年龄与肝移植。
J Hepatol. 2019 Apr;70(4):745-758. doi: 10.1016/j.jhep.2018.12.009. Epub 2018 Dec 18.
2
Liver transplantation in elderly patients: a systematic review and first meta-analysis.老年患者肝移植:系统评价和首次荟萃分析。
HPB (Oxford). 2019 Jan;21(1):14-25. doi: 10.1016/j.hpb.2018.07.025. Epub 2018 Aug 23.
3
A preoperative prognostic model to predict surgical success in patients with perihilar cholangiocarcinoma.一种预测肝门部胆管癌患者手术成功率的术前预后模型。
巴基斯坦一家三级护理医院对慢性肝病患者肝移植资格的评估:一项横断面研究
Cureus. 2024 May 24;16(5):e61028. doi: 10.7759/cureus.61028. eCollection 2024 May.
4
Cholangiocarcinoma: The Current Status of Surgical Options including Liver Transplantation.胆管癌:包括肝移植在内的手术选择现状
Cancers (Basel). 2024 May 21;16(11):1946. doi: 10.3390/cancers16111946.
5
Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma.胆管癌定向分子疗法的当前及未来治疗靶点
Cancers (Basel). 2024 Apr 26;16(9):1690. doi: 10.3390/cancers16091690.
6
Systemic Neoadjuvant and Adjuvant Therapies in the Management of Hepatocellular Carcinoma-A Narrative Review.肝细胞癌治疗中的全身新辅助和辅助治疗——一项叙述性综述
Cancers (Basel). 2023 Jul 5;15(13):3508. doi: 10.3390/cancers15133508.
7
Current Perspectives in Liver Transplantation for Perihilar Cholangiocarcinoma.肝门部胆管癌肝移植的现状。
Curr Oncol. 2023 Mar 1;30(3):2942-2953. doi: 10.3390/curroncol30030225.
8
Outcomes After Liver Transplantation With Incidental Cholangiocarcinoma.肝移植治疗偶然胆管癌的结果。
Transpl Int. 2022 Nov 2;35:10802. doi: 10.3389/ti.2022.10802. eCollection 2022.
9
Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis.原发性硬化性胆管炎患者胆管癌的发病率及治疗结局综述。
World J Gastrointest Oncol. 2021 Oct 15;13(10):1336-1366. doi: 10.4251/wjgo.v13.i10.1336.
10
Cholangiocarcinoma and liver transplantation: What we know so far?胆管癌与肝移植:我们目前所了解的情况?
World J Gastrointest Pathophysiol. 2021 Sep 22;12(5):84-105. doi: 10.4291/wjgp.v12.i5.84.
J Surg Oncol. 2018 Sep;118(3):469-476. doi: 10.1002/jso.25174. Epub 2018 Aug 21.
4
Frailty in Patients With Cirrhosis.肝硬化患者的衰弱
Curr Treat Options Gastroenterol. 2018 Jun;16(2):215-225. doi: 10.1007/s11938-018-0179-x.
5
Low Skeletal Muscle Density Is Associated with Early Death in Patients with Perihilar Cholangiocarcinoma Regardless of Subsequent Treatment.无论后续治疗如何,肝门部胆管癌患者骨骼肌密度低与早期死亡相关。
Dig Surg. 2019;36(2):144-152. doi: 10.1159/000486867. Epub 2018 Feb 16.
6
New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin.胆管癌的新见解:多个起源干细胞及相关细胞谱系
Ann Gastroenterol. 2018 Jan-Feb;31(1):42-55. doi: 10.20524/aog.2017.0209. Epub 2017 Nov 2.
7
A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort.一个包含肌肉减少症的模型在预测肝硬化肝移植候选者等待名单死亡率方面优于 MELD 评分:一项全国队列的竞争风险分析。
J Hepatol. 2018 Apr;68(4):707-714. doi: 10.1016/j.jhep.2017.11.030. Epub 2017 Dec 6.
8
The prognostic value of portal vein and hepatic artery involvement in patients with perihilar cholangiocarcinoma.门静脉和肝动脉受累对肝门部胆管癌患者的预后价值。
HPB (Oxford). 2018 Jan;20(1):83-92. doi: 10.1016/j.hpb.2017.08.025. Epub 2017 Sep 25.
9
Conditional survival in patients with unresectable perihilar cholangiocarcinoma.无法切除的肝门周围胆管癌患者的条件生存情况。
HPB (Oxford). 2017 Nov;19(11):966-971. doi: 10.1016/j.hpb.2017.07.004. Epub 2017 Jul 25.
10
Organ Transplantation in the Face of Donor Shortage - Ethical Implications with a Focus on Liver Allocation.面对供体短缺的器官移植——以肝脏分配为重点的伦理问题
Visc Med. 2016 Aug;32(4):278-285. doi: 10.1159/000446382. Epub 2016 Jun 13.